2023 Novo Holdings Asia Investments Annual Review/Business Update
· Increasing momentum as we expanded our portfolio of investments, built the team and fostered new partnerships
· Three new portfolio company investments and two existing portfolio company financing extensions
· First ever Novo Nordisk and Novo Holdings Partnering Day focusing on Cardio Metabolic disease
Copenhagen, Denmark, 3 April 2024 – Novo Holdings Asia Investments team today publishes its annual review– a year of developing and building for long-term results.
Novo Holdings established the Asian life sciences investment platform in 2020, with offices in Singapore and expanded to Shanghai in 2022. The Asia Investments team is committed to identifying and investing in life science and healthcare companies that are leading innovators in their field. Investments in Asia complement and diversify Novo Holdings life science investment portfolio outside of Europe and the U.S. and look to harness the potential offered by the continent’s market size, growth and quality of innovation. The Team’s key focus markets are India, South-East Asia and China.
